Royal Bank Of Canada Aprea Therapeutics, Inc. Transaction History

Royal Bank Of Canada

$471 Billion
Q3 2024

Shares

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held	SEC Form
Q2 2022 Aug 15, 2022	SELL	$0.62 - $1.94 $7,254 - $22,698	-11,700 Closed	0 $0
Q4 2021 Feb 14, 2022	SELL	$2.87 - $5.58 $25,543 - $49,662	-8,900 Reduced 43.2%	11,700 $34,000
Q3 2021 Nov 15, 2021	SELL	$3.43 - $5.63 $1,886 - $3,096	-550 Reduced 2.6%	20,600 $105,000
Q2 2021 Aug 16, 2021	BUY	$4.05 - $5.5 $85,657 - $116,325	21,150 New	21,150 $104,000

Others Institutions Holding APRE

# of Institutions

1

Shares Held

0

Call Options Held

0

Put Options Held

0

Concourse Financial Group Securities, Inc. Birmingham, AL

0
Shares

$0
0.0% of portfolio

About Aprea Therapeutics, Inc.

Ticker APRE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Description
Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel cancer therapeutics that target DNA damage response pathways. Its lead product candidate is ATRN-119, an oral ATR inhibitor that is in phase 1/2a clinical trial to treat patients with advanced solid tumors. The company's products...

More about APRE

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Royal Bank Of Canada, based on Form 13F filings with the SEC.

News

Stay updated on Royal Bank Of Canada with notifications on news.